SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Accelrys Inc., a wholly owned
subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP), today announced the
introduction of its latest Discovery Studio(TM) release: Discovery Studio
SeqStore. Scheduled for commercial availability in October 2002, DS SeqStore
is a complete, Oracle(R) based enterprise solution for managing, analyzing,
and visualizing genomic and proteomic sequence data.
Designed to meet the needs of biologists, bioinformaticians, and database
administrators, DS SeqStore provides robust and flexible data management
capabilities, a secure environment for research and collaboration, up-to-date
sequence data, and seamless integration with the GCG(R) Wisconsin Package(R).
DS SeqStore enables life science research organizations to effectively utilize
the vast volumes of genomic and proteomic sequence data available today. It
delivers a unified environment for managing public, proprietary and
third-party data that can be integrated with proprietary and third-party
analysis applications. As such, the solution provides a single point of
access for all of an organization's research data, analysis and visualization
DS SeqStore represents the latest addition to the Discovery Studio family
of products and furthers Accelrys' strategy of providing comprehensive and
integrated bioinformatics and proteomics solutions. DS SeqStore complements
DS Gene, Accelrys' first Discovery Studio bioinformatics product, and provides
powerful scientific tools with comprehensive knowledge management capabilities
to enable knowledge transfer across the enterprise. Within DS SeqStore users
can register new sequences, record analysis results, annotate existing
sequences as new discoveries are made, and integrate and manage data from
multiple sources in multiple formats. Users can also save multiple versions
of sequences and annotations, enhancing collaboration and recording discovery
histories for patent purposes. DS SeqStore automatically updates the database
as new information becomes available, giving researchers across the
organization access to the most current data.
DS SeqStore will be demonstrated at the Genome Sequencing and Analysis
Conference (GSAC) in Boston this week. Please visit us there in Booth # 317.
Discovery Studio is a powerful research environment for the life sciences
that delivers a comprehensive suite of informatics, modeling, and simulation
solutions. This enterprise-wide family of products is composed of a wide
breadth of tools, client-server applications, and databases for handling the
specific research problems encountered by scientists working in the discovery
process. The Discovery Studio design enables collaboration across scientific
disciplines through a centralized project and knowledge management system,
connecting the research conducted by biologists and chemists. In addition,
Discovery Studio is an open platform built on industry-standard components so
that it can leverage existing IT infrastructure and the integration of
third-party applications, public domain, and other in-house developed
About Accelrys Inc.
Accelrys is a leading provider of software for computation, simulation,
and the management and mining of scientific data used by biologists, chemists,
and materials scientists for product design, drug discovery, and development.
Accelrys' platform technology and consulting services enable enterprise-wide
solutions tailored to today's leading research organizations. The company's
two main centers of excellence are in San Diego, and Cambridge, UK. These
centers combine research and product development with facilities to support
significant collaborative projects. Accelrys is a subsidiary of
Pharmacopeia, Inc. (Nasdaq: PCOP) and was launched in June 2001, combining
leading software companies Molecular Simulations Inc., Synopsys Scientific
Systems, Oxford Molecular, GCG, and Synomics Ltd.
More information on Accelrys can be found at http://www.accelrys.com.
Discovery Studio is a registered trademark of Accelrys Inc. within the
United States and/or various other countries.
When used anywhere in this document, the words expects, believes,
anticipates, estimates, and similar expressions are intended to identify
forward-looking statements. Forward-looking statements herein may include
statements addressing future financial and operating results of Pharmacopeia.
Pharmacopeia has based these forward-looking statements on its current
expectations about future events. Such statements are subject to risks and
uncertainties including, but not limited to, the successful implementation of
Pharmacopeia's strategic plans, the acceptance of new products, the
obsolescence of existing products, the resolution of existing and potential
future patent issues, additional competition, changes in economic conditions,
and other risks described in documents Pharmacopeia has filed with the
Securities and Exchange Commission, including its most recent report on Form
10-K and subsequent reports on Form 10-Q. All forward-looking statements in
this document are qualified entirely by the cautionary statements included in
this document and such filings. These risks and uncertainties could cause
actual results to differ materially from results expressed or implied by
forward-looking statements contained in this document. These forward-looking
statements speak only as of the date of this document. Pharmacopeia disclaims
any undertaking to publicly update or revise any forward-looking statements
contained herein to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such
statement is based.
MAKE YOUR OPINION COUNT - Click Here
SOURCE Accelrys, Inc.